Sugi Predict

Sugi Predict / Compounds / SCHEMBL1773383

SCHEMBL1773383

SCHEMBL1773383

CC(C)(C)OC(=O)C(C)(C)/N=C/c1ccccc1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGER3 P43115 4/20 0.39
▸ PTGDR Q13258 4/20 0.39
▸ TBXA2R P21731 3/20 0.39
▸ PTGER2 P43116 3/20 0.39
▸ ITGA4 P13612 1/20 0.37
▸ ITGB7 P26010 1/20 0.37
▸ PPARA Q07869 2/20 0.36
▸ PPARG P37231 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ HRH1 P35367 3/20 0.35
▸ PTGER4 P35408 2/20 0.34
▸ PTGFR P43088 2/20 0.34
▸ IDO1 P14902 1/20 0.34
▸ AKT1 P31749 2/20 0.34
▸ PTGER1 P34995 1/20 0.34
▸ PTGIR P43119 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1773384 1.00 PTGER3 (0.39) PTGER3PTGDRTBXA2RPTGER2ITGA4
SCHEMBL28354000 0.75 PTGER3 (0.53) PTGER3PTGDRTBXA2RPTGER2HRH1
SCHEMBL1774203 0.69 CA12 (0.43) ITGA4ITGB7PPARAPPARGL3MBTL1
SCHEMBL10798008 0.69 HPGD (0.44) PTGER3PTGDRTBXA2RPTGER2L3MBTL1
SCHEMBL28517659 0.68 LMNA (0.45) PTGER3PTGDRTBXA2RPTGER2L3MBTL1
SCHEMBL28517655 0.68 LMNA (0.45) PTGER3PTGDRTBXA2RPTGER2L3MBTL1
SCHEMBL31588310 0.65 LMNA (0.52) PTGER3PTGDRTBXA2RPTGER2L3MBTL1
SCHEMBL872046 0.65 LMNA (0.52) PTGER3PTGDRTBXA2RPTGER2L3MBTL1
SCHEMBL6369251 0.65 MAOB (0.44) CA1CA7
SCHEMBL7091384 0.65 MMP8 (0.46) PPARAPPARGCA12CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 — — US disclosed
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 — — US disclosed
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 — — US disclosed
WO-2009097997-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC PTGER3 1071/4885PTGDR 108/4885TBXA2R 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.